LC-MS/MS determination and pharmacokinetic study of five flavone components after solvent extraction/acid hydrolysis in rat plasma after oral administration of Verbena officinalis L. extract

Ethnopharmacological relevance

Traditional Chinese medicine (TCM) has been used in clinical practice for several thousand years. TCM has played an indispensable role in the prevention and treatment of diseases, especially the complicated and chronic ones. Pharmacokinetic study on active constituents in herbal preparations is a good way for us to explain and predict a variety of events related to the efficacy and toxicity of TCM.

Aim of the study

A selective and sensitive HPLC-MS/MS method was first developed and validated for the determination of luteolin, kaempferol, apigenin, quercetol, and isorhamnetin in rat plasma.

Materials and methods

The LC system consisted of an Agilent Technologies Series 1200 system (Agilent, USA) equipped with an automatic degasser, a quaternary pump, and an autosampler. Chromatographic separations were performed on a Waters SunFire™ C₁₈ column (150 mm × 4.6 mm, 5 μm), and the column temperature was maintained at 25 °C and the sample injection volume was 20 μL. The current LC-MS/MS assay was validated for linearity, intra-day and inter-day precisions, accuracy, extraction recovery and stability.

Results

The validated method was successfully applied to monitoring the concentrations and pharmacokinetic studies of five flavone compounds in rat plasma after a single oral administration of Verbena officinalis L. extract with a dosage of 8.0 mL/kg. The time to reach the maximum plasma concentration (T_max1) was 0.48 ± 2.14 h for luteolin, 0.25 ± 0.13 h for kaempferol, 0.97 ± 1.08 h for apigenin, 1.04 ± 4.25 h for quercetol and 0.25 ± 0.16 h for isorhamnetin, and the maximum plasma concentration (T_max2) was 3.97 ± 1.48 h, 4.05 ± 0.46 h, 4.33 ± 0.58 h, 2.99 ± 0.48 h and 4.02 ± 0.34 h. The elimination half-time (t_1/2) of luteolin, kaempferol, apigenin, quercetol and isorhamnetin was 4.02 ± 0.81, 7.65 ± 0.71, 3.30 ± 0.83, 4.55 ± 0.49 and 5.56 ± 1.32 h, respectively.

Conclusions

This paper described a simple, sensitive and validated LC-MS/MS method for simultaneous determination of luteolin, kaempferol, apigenin, quercetol and isorhamnetin in rat plasma after oral administration of V. officinalis L. extract, and investigated on their pharmacokinetic studies as well, with a short run time of 5 min.     

Beagle犬口服雷公藤片血浆中雷公藤红素LC-MS/MS测定及药动学研究

建立Beagle犬血浆中雷公藤红素的LC-MS/MS检测方法,用于Beagle犬口服雷公藤片的药代动力学研究。血浆样品经二氯甲烷提取,色谱条件为Phenomenex Luna C8色谱柱(2.0 mm×50 mm,3μm),流动相为甲醇-乙腈异丙醇溶液(1∶1)-0.1%甲酸15∶55∶30;多反应监测(MRM)雷公藤红素([M+H]+,m/z 451.3/201.1)和内标泼尼松龙([M+H]+,m/z 361.1/147.1);DAS 1.0软件对雷公藤红素药-时曲线进行拟合,并计算药代动力学参数。在0.680 0~136.0μg·L-1,雷公藤红素与内标的峰面积比值与浓度的线性关系良好,定量限为0.680 0μg·L·(-1),日内日间精密度小于6.15%,提取回收率为50.42%~51.65%。Beagle犬口服雷公藤片(1片/kg),血浆中雷公藤红素经时变化符合一室模型(w=1/cc),主要药动学参数分别为Cmax(35.64±9.540)μg·L~(-1),Tmax(2.62±0.69)h,T1/2(2.93±0.29)h,CL(0.308±0.056)L·kg~(-1)·h~(-1),AUC0-12(131.16±31.94)μg·L·h~(-1),AUC0-∞(142.83±37.57)μg·L·h~(-1)。建立的LC-MS/MS分析方法准确灵敏,适于雷公藤片中雷公藤红素药代动力学研究。     

Identification and pharmacokinetics of multiple constituents in rat plasma after oral administration of Yinchenzhufu decoction

Ethnopharmacological relevance

Yinchenzhufu decoction (YCZFD) is a classical Chinese herbal formula and has been used to treat severe jaundice in chronic liver injuries since the Qing Dynasty (18th century CE). To identify the components absorbed into the blood in YCZFD and explore their pharmacokinetic profile for understanding the effective ingredients of YCZFD.

Materials and methods

After rats were given YCZFD by intragastric administration, the plasma was processed by precipitation of protein. The compounds in YCZFD extract and the plasma were identified by using high-resolution mass spectrometry with a database-directed strategy. The pharmacokinetics of multiple compounds from YCZFD in rat plasma was studied by using the established UPLC-MS/MS method.

Results

Forty compounds in YCZFD extract and 21 prototype compounds with 11 metabolites in rat plasma were detected after oral administration. The pharmacokinetic parameters of glycyrrhizic acid, glycyrrhetic acid, cinnamic acid, ononin, atractylenolide III, and liquiritin from YCZFD were obtained in rats.

Conclusions

The identified constituents and the pharmacokinetic features of YCZFD are helpful for understanding the material bases of its therapeutic effects.     

基于UPLC-Q-TOF/MS的复方鱼腥草合剂大鼠血清药物化学研究

目的 采用超高效液相色谱-四极杆-飞行时间质谱联用技术(UPLC-Q-TOF/MS)对复方鱼腥草合剂口服吸收入血成分进行辨识研究,初步阐明其可能的药效物质基础.方法 采用Acquity BEHC18(100mm×2.1 mm,1.7 μm)色谱柱,流动相为0.1％甲酸水溶液(A)-乙腈(B),梯度洗脱,体积流量0.2 ...     

LC-MS/MS同时测定大鼠血浆中瑞香素、西瑞香素和瑞香新素及其药代动力学研究

建立同时测定大鼠灌胃祖师麻提取物后血浆中瑞香素、西瑞香素和瑞香新素的HPLC-MS/MS分析方法,并用于计算3个成分在大鼠体内的药代动力学参数。试验采用6只SD大鼠,口服给予祖师麻提取物(瑞香素、西瑞香素和瑞香新素的给药量分别是88.40,3.24,4.28 mg·kg~(-1)),以五味子醇甲为内标,用LC-MS/MS测定给药后血浆中药物浓度,绘制血药浓度-时间曲线,并用Kinetica 4.4软件计算相关药代动力学参数。试验结果显示,瑞香素、西瑞香素和瑞香新素的线性范围均为5~1 000μg·L~(-1),方法学考察符合要求。日内、日间变异系数(RSD)均小于15%,精密度和准确度符合生物样品分析要求。瑞香素、西瑞香素和瑞香新素口服给药后的T_(max)分别为4,2.92,2 h;C_(max)分别为858.96,178.00,36.67μg·L~(-1);AUC_(0-t)分别为10 566.4,905.89,355.11μg·L~(-1)·h;半衰期t1/2分别为5.19,3.50,4.95 h;平均驻留时间MRT分别为9.43,6.95,8.27 h。因此,该研究建立的LC-MS/MS分析方法准确灵敏,适于对SD大鼠口服祖师麻提取物后的瑞香素、西瑞香素和瑞香新素的药代动力学研究。     

基于UPLC-ESI-MS/MS的何首乌中12种真菌毒素污染检测

通过测定何首乌中多种真菌毒素的含量,探讨其致肝毒性原因。采用高效液相色谱-串联质谱法检测何首乌中黄曲霉毒素B1,B2,G1,G2,赭曲霉毒素A,B,T-2毒素,HT-2毒素,伏马毒素B1,B2,玉米赤霉烯酮和脱氧雪腐镰刀菌烯醇共12种真菌毒素的含量。样品采用改良的Qu ECh ERS方法提取,使用Welch Ultimate XBC18色谱柱(4.6 mm×100 mm,2.5μm)分离,甲醇-含0.1%乙酸的2 mmol·L~(-1)醋酸铵水溶液为流动相梯度洗脱,多反应监测模式下测定,外标法定量。结果表明,12种真菌毒素在0.1~200μg·kg~(-1)线性关系良好,相关系数为0.996 3~0.999 9,加标回收率为71.19%~98.68%,相对标准偏差为1.7%~13%。该方法操作简单、准确、灵敏,可用于何首乌中多种真菌毒素的快速测定。结果显示,41批样品中的15批检出了真菌毒素,涉及毒素类型有AFB1,AFG2,FB1,OTB,T-2,HT-2,FB2和OTA共8种,毒素在0.51~1 643.2μg·kg~(-1)。其中1批制首乌中检测到AFB1,达6.8μg·kg~(-1),超出了其在2015年版《中国药典》中的限量标准(5μg·kg~(-1))。AFB1具有明确的肝毒性。因此,推测何首乌在产地加工、储存运输过程中产生的少量霉变样品是其导致肝损伤的重要因素之一。     

LC/MS/MS测定人血浆中茚地那韦的浓度

 目的建立LC/MS/MS测定人血浆中茚地那韦的浓度。方法以利托那韦为内标,采用10 mmol·L^-1乙酸胺缓冲液(pH 4.10)-含0.1%甲酸的乙腈溶液(20:80)为流动相,以ZORBAX Eclipse XDB-C₈色谱柱为分析柱,通过电喷雾电离源(ESI),以选择离子反应监测(SRM)方式进行检测。用于定量分析的离子反应分别为m/z 614.4→421.2(茚地那韦)和m/z 721.3→296.0 (利托那韦)。结果茚地那韦线性范围0.009～30.0 mg·L^-1,定量下限为(0.010±0.001)mg·L^-1(n=5)。日内、日间精密度(RSD)小于4%,平均回收率大于90%。结论本法专属性强,样品处理方便,灵敏度高,适用于茚地那韦临床药动学研究。     

Pharmacokinetics of aconitine as the targeted marker of Fuzi (Aconitum carmichaeli) following single and multiple oral administrations of Fuzi extracts in rat by UPLC/MS/MS

Ethnopharmacological relevance

Fuzi, which is the processed lateral roots of Aconitum Carmichaeli. Debx and is widely distributed over the southwest provinces of China, is recognised for its anti-inflammatory and analgesic effects.

Aim of the study

The pharmacokinetic properties of Fuzi are inadequately understood. Aconitine, the primary highly toxic ingredient of Fuzi, is well known as the target marker of Fuzi. The purpose of the present study is to investigate the pharmacokinetic behaviours of aconitine in vivo following single and multiple administrations of processed Fuzi extracts and to compare the pharmacokinetic characteristics of aconitine after administrations of pure aconitine or Fuzi extracts as well as compare the difference at single dose and multiple doses. The in vitro aconitine protein binding in plasma through equilibrium dialysis was also examined.

Methods

A high performance liquid chromatography (HPLC) method was developed for the determination of aconitine in Fuzi crude extracts and a fast ultra performance liquid chromatography-tandem mass spectrometry (UPLC/MS/MS) was developed to investigate the pharmacokinetic behaviour of aconitine as the targeted marker of Fuzi.

Results

The absolute bioavailability (F %) after the administration of 0.5 mg/kg aconitine and Fuzi extract (0.118 mg/kg aconitine) in rat was 8.24 ± 2.52% and 4.72 ± 2.66%, respectively. Aconitine absorption was very fast at the t_max 30.08 ± 9.73 min for pure aconitine and 58.00 ± 21.68 min for Fuzi extract administration. Aconitine was also eliminated rapidly with a short half-life (i.v., 80.98 ± 6.40 min) and a low rate of protein bounding (23.9–31.9%). No significance was observed on all the pharmacokinetics parameters following the single and multiple doses of pure aconitine (ANOVA, p > 0.05). However, the absorption of aconitine after multiple administrations of Fuzi extract was much faster than that of a single dose (t_max: 58.00 ± 21.68 vs. 20.00 ± 8.66 min, p < 0.05), and the area under the plasma concentration–time curve (AUC) was higher than that of a single dose.

Conclusions

The pharmacokinetic behaviour of processed Fuzi was determined in this paper. The aconitine has low bioavailability. No variation in the pharmacokinetic behaviours of pure aconitine was observed after single and multiple administrations. In contrast, multiple administrations of processed Fuzi extract could result in variations in its pharmacokinetic behaviour in AUC and t_max indicating that multiple dose might increase the bioavailability of aconitine, which may result in its toxicity. In addition, aconitine has a low protein bounding (23.9–31.9%), resulting in its rapid elimination.     

UPLC-MS/MS-ESI assay for simultaneous determination of magnolol and honokiol in rat plasma: Application to pharmacokinetic study after administration emulsion of the isomer

Ethnopharmacological relevance

Magnolia officinalis is one of the commonly used in traditional Chinese medicine for the treatment of fever, chronic bronchitis and stomach ailments. Magnolol and honokiol are isomers with hydroxylated biphenol compound in the extract of Magnolia officinalis. This study aims to determine the isomers in rat plasma and evaluate their pharmacokinetic pattern after administration emulsion.

Materials and methods

Sprague Dawley male rats received either an intravenous (i.v.25, mg/kg) or oral (50 mg/kg) dose of the emulsion of the isomer. A sensitive and specific ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) method was developed for the investigation of the pharmacokinetics of magnolol and honokiol in rats. Kaempferol was employed as an internal standard.

Results

The plasma samples were deproteinized with acetonitrile, the post-treatment samples were analyzed on an Agela C₁₈ column interfaced with a triple quadrupole tandem mass spectrometer in negative electrospray ionization mode. Acetonitrile and 5 mmol/L ammonium acetate buffer solution (65: 35, v/v) was used as the mobile phase at a flow rate of 0.2 mL/min. Following oral administration of emulsion to rats, magnolol attained mean peak plasma concentrations of 426.4±273.8 ng/mL at 1.20 h, whereas honokiol reached peak plasma concentrations of 40.3±30.8 ng/mL at 0.45 h. The absolute bioavailability of magnolol and honokiol is 17.5±9.7% and 5.3±11.7%. By comparison, the AUC_0–∞ of magnolol was 5.4 times higher than that of honokiol after intravenous administration, but AUC_0–∞ of magnolol was about 18-fold higher than honokiol after oral administration.     

LC-MS/MS测定6种丹参主要有效成分及其脑靶向分布研究

建立测定大鼠血浆及脑匀浆中原儿茶酸、原儿茶醛、丹酚酸A、丹酚酸B、隐丹参酮、丹参酮ⅡA的LC-MS/MS分析方法。实验采用液液萃取的方法对血浆及脑匀浆样品进行处理,采用Agilent Eclipse Plus-C18色谱柱(2.1 mm×50 mm,3.5μm),以0.1%甲酸乙腈和0.1%甲酸水为流动相进行梯度洗脱。质谱条件为电喷雾电离源(ESI),多反应监测(MRM)。正离子模式下检测的离子对(m/z)为297.4/254.3(隐丹参酮),295.5/249.3(丹参酮ⅡA),285.2/154.0(内标地西泮);负离子模式下检测的离子对(m/z)为154.3/153.1(原儿茶酸),137.3/108(原儿茶醛),493.0/295.2(丹酚酸A),718.0/520.0(丹酚酸B),321.4/152.3(内标氯霉素)。血浆及脑匀浆中隐丹参酮、丹参酮ⅡA、原儿茶酸、原儿茶醛、丹酚酸A、丹酚酸B的线性范围分别为:0.15~1 000,0.625~1 000,0.625~1 000,0.625~1 000,1.25~1 000,2.5~1 000μg·L-1;定量下限分别为0.15,0.625,0.625,0.625,1.25,2.5μg·L-1。建立的方法稳定、灵敏,可用于研究丹参6种成分的脑及血浆药物代谢动力学特性。通过动物实验比较了6种成分之间的血脑分配系数,初步评价其跨越血脑屏障的能力。     

LC-MS/MS 测定大鼠血浆中香柑内酯及其药代动力学研究

目的:建立测定香柑内酯(berg)血浆药物浓度的液相色谱-电喷雾离子化-质谱(LC-ESI-MS)联用的分析方法,并探讨其在大鼠体内的药动学。方法:采用Hypersil ODS柱(4.6 mm×250 mm,5 mm),流动相甲醇-水(77.5∶2.5),流速0.8mL.min-1,柱温30℃,检测波长300 nm。结果:Berg在8.12～162.4μg.L-1(r=0.999 9)线性关系良好。方法学考察均符合要求。日内、日间变异系数(RSD)均<10%,精密度和准确度等均符合生物样品分析的要求。结论:该法准确、灵敏、特异,适用于berg的体内定量分析,berg在大鼠体内药动学过程属于一级吸收二室模型。     

LC-MS/MS法同时测定犬血浆中延胡索乙素和欧前胡素及其在元胡止痛片药动学研究中的应用

目的建立同时测定Beagle犬血浆中的延胡索乙素和欧前胡素的LC-MS/MS分析方法,并应用于元胡止痛片的药动学研究。方法采用液-液萃取方式进行样品处理,萃取剂为甲基叔丁基醚,内标为乙氧苯柳胺;采用XDB-C18(50 mm×4.6 mm,5μm)柱色谱分离,柱温40℃,体积流量0.4 m L/min;流动相为甲醇-0.1%甲酸水溶液,梯度洗脱;采用电喷雾离子源(ESI)、正离子扫描、多反应离子监测(MRM)进行测定,延胡索乙素:m/z 356.2[M+H]+→m/z 192.1,欧前胡素:m/z 271.1[M+H]+→m/z 203.0,内标乙氧苯柳胺:m/z 258.1[M+H]+→m/z 121.1。应用Win Nonlin 6.3软件非房室模型统计矩方法计算药动学参数。结果延胡索乙素在0.05~20 ng/m L线性良好,欧前胡素在0.005~2 ng/m L线性良好,延胡索乙素和欧前胡素的定量下限分别为0.05 ng/m L和0.005 ng/m L;批内和批间精密度均小于14.4%,准确度均在–7.19%~5.89%;提取回收率在82.8%~108%,基质效应在88.2%~109%。Beagle犬po给予元胡止痛片后,延胡索乙素的主要药动学参数tmax、Cmax、AUC0~t、AUC0~∞、MRT0~t、MRT0~∞、Vd、CL和t1/2分别为(1.08±0.20)h、(48.70±18.10)ng/m L、(170.00±75.70)h·ng/m L、(178.00±77.50)h·ng/m L、(6.41±1.13)h、(8.09±1.85)h、(133.00±63.00)L、(11.90±5.54)L/h和(7.71±1.07)h;欧前胡素的主要药动学参数tmax、Cmax、AUC0~t、AUC0~∞、MRT0~t、MRT0~∞、Vd、CL和t1/2分别为(1.17±0.26)h、(0.063 4±0.023 5)ng/m L、(0.176 0±0.091 9)h·ng/m L、(0.204 0±0.097 3)h·ng/m L、(2.550±0.669)h、(3.640±0.818)h、(22 351±7 990)L、(7 917±6 030)L/h和(2.390±0.877)h。结论该分析方法专属性强,灵敏度高,能同时测定犬血浆中延胡索乙素和欧前胡素,可用于元胡止痛片给药后犬的药动学研究。     

LC-MS/MS测定人尿液中阿德福韦及其排泄动力学研究

 目的建立测定人尿液中阿德福韦的LC-MS/MS,进行阿德福韦酯po给药排泄动力学研究。方法志愿者尿样经离心、稀释后直接进样,色谱柱为Diamonsil C₁₈柱(4.6mm×250mm,5μm),流动相为甲醇-水-甲酸(20:80:0.1),流速0.6mL·min^-1,采用电喷雾离子化四极杆串联质谱,多反应监测方式测定样品浓度,监测离子对为m/z274→m/z162。结果在0.05～8.0 mg·L^-1内线性关系良好(r=0.9978,n=5),最低定量限为0.05mg·L^-1。低、中、高浓度质控样品的日内、日间精密度小于10%,方法回收率96.3%～99.3%。志愿者分别服用10,20,40mg阿德福韦酯,尿中阿德福韦排泄率分别为(34±4)%,(36±10)%和(35±14)%,排泄速率常数k_e分别为(0.055±0.028),(0.066±0.016)和(0.06±0.04)h^-1。结论该方法符合生物样品分析要求,可用于阿德福韦尿液浓度的测定,阿德福韦排泄率ke中国人与国外文献报道一致。     

宝儿康散大鼠ig给药后血浆暴露成分分析

目的分析大鼠ig宝儿康散后在血浆中的暴露成分,为其作用机制及药动学研究奠定基础。方法采用超高效液相色谱-高分辨飞行时间质谱联用技术(UPLC-Q-TOF/MS),分离给药后吸收入血成分。根据化合物的保留时间,相对分子质量及二级质谱特征碎片,结合文献报道,分析鉴定大鼠血浆中宝儿康散化学成分。结果大鼠ig宝儿康散1 h后,在血浆中分离鉴定了23个化合物,其中有5个化合物通过与对照品比对保留时间与质谱数据,确定了化学结构,分别为牡荆素、甘草素、橙皮素、甘草次酸、熊果酸。结论本方法可以快速分析宝儿康散大鼠ig给药后血浆暴露成分,对进一步探究其作用机制及其药动学奠定了基础。     

LC-MS/MS测定人血浆中格列本脲的浓度

 目的建立LC-MS/MS测定人血浆中格列本脲浓度的方法。方法以格列齐特为内标,采用0.1%甲酸-乙腈(35∶65)为流动相,以ZORBAX Eclipse XDB-C₁₈色谱柱为分析柱,通过电喷雾电离源(ESI),以选择离子反应监测(SRM)方式进行检测。用于定量分析的离子反应分别为m/z 494.2→368.9(格列本脲)和m/z 324.0→126.9(格列齐特)。结果格列本脲线性范围6.67～500μg·L^-1,定量下限为(6.67±0.3)μg·L^-1(n=5)。日内、日间精密度(RSD)小于8%,平均回收率大于90%。结论本法专属性强,样品处理方便,灵敏度高,适用于格列本脲临床药动学研究。     

UPLC-MS/MS同时测定大承气汤大鼠血浆中9种活性成分的含量

该研究建立了大鼠血浆中大承气汤9种活性成分同时测定的UPLC-MS/MS方法。采用Aglient C₁₈色谱柱（2.1 mm×50 mm,1.7 μm）进行色谱分离,利用甲醇-5 mmol·L^-1甲酸铵流动相进行梯度洗脱,流速0.3 mL·min^-1。实验过程血浆的前处理不仅考察了甲醇、乙腈等有机溶剂蛋白沉淀法,同时考察了液-液萃取法中不同萃取溶剂、不同涡旋时间、萃取次数及不同体积萃取溶剂等因素对各活性成分回收率的影响。最终确定以布洛芬为内标,采用乙酸乙酯液-液萃取法进行血样前处理,N₂吹干复溶,离心后上清液进行UPLC-MS/MS分析,在电喷雾电离（ESI）负离子模式下,采用多重反应监测模式进行检测。大黄素、大黄酸、芦荟大黄素、大黄素甲醚、大黄酚、厚朴酚、和厚朴酚、橙皮苷及橙皮素的线性范围分别为0.33~660,0.40~792,0.41~827,0.34~680,0.45~907,0.46~927,0.43~867,0.34~683,0.39~787 μg·L^-1,且线性关系良好;提取回收率均>69.39%;日内和日间的RSD<15%。该方法符合生物样品分析的要求,可用于研究大鼠灌胃大承气汤后,血浆中该9种活性成分的同时测定,为其量-效物质基础提供了理论依据。     

LC-MS/MS法同时测定大鼠血浆中士的宁及其代谢物

目的建立LC-MS/MS法同时测定士的宁及其代谢物士的宁氮氧化物在大鼠血浆中的浓度。方法以盐酸麻黄碱为内标,甲醇沉淀法处理血浆样品。采用ZORBAX Eclipse XDB-C18柱(2.1 mm×150 mm,3.5μm)分离,以甲醇-10 mmol·L-1乙酸铵(用甲酸调p H=4)为流动相进行梯度洗脱,流速0.2 m L·min-1,用电喷雾离子化和正离子多离子反应监测(MRM)模式检测士的宁和士的宁氮氧化物。结果士的宁及其氮氧化物的线性范围分别为0.510~306.3 ng·m L-1和0.102~306.0 ng·m L-1,定量下限分别为0.510,0.102 ng·m L-1,日内、日间相对标准偏差(RSD)均15%,准确度分别为(89.44±3.43)%~(97.45±6.25)%和(95.86±5.19)%~(106.41±7.43)%。结论该方法准确、灵敏、特异、简便,适用于血浆中士的宁及其代谢物士的宁氮氧化物含量的同时测定。     

UPLC-MS/MS快速同时测定犬血浆中补骨脂的10个活性成分及补骨脂犬药代动力学研究

建立了同时测定犬血浆中补骨脂的10个活性成分——补骨脂素、异补骨脂素、5,7,4'-三羟基黄酮、5,7,4'-三羟基异黄酮、补骨脂宁、新补骨脂异黄酮、补骨脂甲素、补骨脂二氢黄酮甲醚、补骨脂苷、异补骨脂苷的UPLC-MS/MS分析方法,并对比格犬灌胃给药补骨脂水提取物后不同时间点血浆中的各成分的浓度进行了测定,绘制了血药...     

LC-MS/MS测定马钱子总碱囊泡凝胶经皮给药后大鼠的血药浓度

目的:建立LC-MS/MS测定大鼠血浆中的马钱子碱和士的宁含量,以溶剂萃取法提取大鼠血浆中的待测成分。方法:以他克林为内标,采用Agilent ZORBAX XDB-C18色谱柱,流动相为乙腈-甲醇-水(0.05%甲酸,10 nmol.L-1甲酸铵)梯度洗脱,质谱采用多反应监测(MRM),用于定量分析的离子对依次为m/z 395.2/324.2(马钱子碱),m/z 335.2/184.2(士的宁)和m/z 199.1/171.1(他克林)。结果:测定血浆样品2种成分的线性范围分别为0.195～100,0.078 1～40μg.L-1,相关系数分别为0.994,0.996,马钱子碱的提取回收率为78.9%～102.4%,士的宁的提取回收率为95.2%～106.1%,方法的精密度、准确度、基质效应和稳定性均符合要求。结论:方法专属性强、灵敏度高,适用于血浆马钱子类生物碱的药代动力学研究。囊泡制剂能够降低马钱子碱进入体循环的药物浓度,且具有缓释作用。     

LC-MS/MS同时测定痛安注射液中13个成分的含量

利用超高效液相色谱-质谱联用仪(UPLC-MS/MS)建立了同时测定痛安注射液(TAI)中丁香脂素、N-反式阿魏酰酪胺、白屈菜红碱、青藤碱、黄连碱、血根碱、白屈菜碱、木兰花碱、别隐品碱、原阿片碱、杜鹃素、次罂粟碱、二氢血根碱共13个有效成分的定性定量检测方法,用于痛安注射液的质量控制。采用Agilent Zorbax SB-Aq C_(18)柱(2.1 mm×150 mm,3.5μm)色谱柱,流动相A为0.1%甲酸水溶液,B为乙腈,梯度洗脱(0.01~2 min,5%B;2~8 min,5%~30%B;8~11 min,30%~95%B;11~13 min,95%B;13~13.1 min,95%~5%B;13.1~14 min,5%B),流速0.5 m L·min~(-1),柱温25℃;电喷雾离子源(ESI)正离子条件下检测,多反应离子监测(MRM)进行定量。结果所测上述13个待测成分在测定的质量浓度范围内均具有良好的线性关系(r0.999 0);加样回收率在95.70%~104.8%,RSD均小于1.9%,10个批次样品中上述13种成分的质量浓度依次为0.021 2~0.029 0,0.001 7~0.002 3,0.000 9~0.001 3,5.952~6.205 2,0.195 4~0.240 5,0.002 0~0.002 9,0.693~0.798 2,0.069 3~0.078 2,0.089 29~0.102 9,0.386 5~0.420 1,0.014 3~0.015 9,0.755 3~0.842 1,0.008 2~0.011 2 g·L~(-1)。经方法学验证,该方法简便、快速、准确、重复性好,可以为综合评价痛安注射液的质量提供参考。通过对10个批次的痛安注射液进行分析测定,并根据含量测定结果表明不同批次痛安注射液的质量并无明显差异,从而为痛安注射液的质量控制提供依据。